NECLF Stock Overview
Manufactures and sells pharmaceutical products in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Nectar Lifesciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹0.51 |
| 52 Week High | ₹0 |
| 52 Week Low | ₹0 |
| Beta | 1.03 |
| 11 Month Change | 16.36% |
| 3 Month Change | 32.20% |
| 1 Year Change | 70.61% |
| 33 Year Change | 27.53% |
| 5 Year Change | 183.71% |
| Change since IPO | -33.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| NECLF | LU Pharmaceuticals | LU Market | |
|---|---|---|---|
| 7D | -11.4% | 0% | 0% |
| 1Y | 70.6% | 0% | 0% |
Return vs Industry: NECLF exceeded the Luxembourg Pharmaceuticals industry which returned 13% over the past year.
Return vs Market: NECLF exceeded the Luxembourg Market which returned 4.4% over the past year.
Price Volatility
| NECLF volatility | |
|---|---|
| NECLF Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in LU Market | 0% |
| 10% least volatile stocks in LU Market | 0% |
Stable Share Price: NECLF's share price has been volatile over the past 3 months.
Volatility Over Time: NECLF's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Luxembourg stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 1,686 | Amit Chadah | www.neclife.com |
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company’s active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins.
Nectar Lifesciences Limited Fundamentals Summary
| NECLF fundamental statistics | |
|---|---|
| Market cap | US$112.28m |
| Earnings (TTM) | US$734.82k |
| Revenue (TTM) | US$197.27m |
152.8x
P/E Ratio0.6x
P/S RatioIs NECLF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NECLF income statement (TTM) | |
|---|---|
| Revenue | ₹16.49b |
| Cost of Revenue | ₹11.60b |
| Gross Profit | ₹4.89b |
| Other Expenses | ₹4.83b |
| Earnings | ₹61.44m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.27 |
| Gross Margin | 29.64% |
| Net Profit Margin | 0.37% |
| Debt/Equity Ratio | 59.4% |
How did NECLF perform over the long term?
See historical performance and comparison